Enovis (NYSE:ENOV) Lowered to "Hold" Rating by Wall Street Zen

Key Points

• Wall Street Zen downgraded Enovis from “Buy” to “Hold,” though the broader analyst consensus remains “Moderate Buy,” with eight Buy, one Hold and one Sell rating and a $42 average price target.
• Enovis exceeded quarterly expectations, reporting $0.90 adjusted EPS versus the $0.85 estimate and $582.8 million in revenue, up 3.2% year over year. Management maintained its 2026 adjusted EPS guidance of $3.52 to $3.73.
• ENOV opened at $26.68, while the company continues to face profitability concerns, including a deeply negative net margin; insiders bought shares recently, and institutional investors own 98.45% of the stock.

Enovis (NYSE:ENOV - Get Free Report) was downgraded by stock analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a research note issued on Saturday.

Several other analysts also recently weighed in on ENOV. Weiss Ratings upgraded Enovis from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Tuesday, July 21st. William Blair started coverage on shares of Enovis in a report on Friday, April 17th. They issued an "outperform" rating on the stock. Zacks Research raised shares of Enovis from a "strong sell" rating to a "hold" rating in a research note on Wednesday, July 29th. BTIG Research upped their price target on shares of Enovis from $39.00 to $40.00 and gave the company a "buy" rating in a report on Thursday. Finally, UBS Group reissued a "buy" rating and set a $51.00 price target (up from $50.00) on shares of Enovis in a research report on Tuesday, July 28th. Eight equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Enovis currently has an average rating of "Moderate Buy" and a consensus price target of $42.00.

Enovis Stock Up 1.4%

ENOV opened at $26.68 on Friday. The company has a market cap of $1.54 billion, a P/E ratio of -1.39 and a beta of 1.34. The business's 50-day moving average price is $24.62 and its 200-day moving average price is $23.97. The company has a current ratio of 1.98, a quick ratio of 1.05 and a debt-to-equity ratio of 0.84. Enovis has a 12 month low of $19.14 and a 12 month high of $34.28.

Enovis (NYSE:ENOV - Get Free Report) last released its earnings results on Thursday, August 6th. The company reported $0.90 earnings per share for the quarter, beating analysts' consensus estimates of $0.85 by $0.05. Enovis had a positive return on equity of 12.03% and a negative net margin of 47.96%.The company had revenue of $582.78 million during the quarter, compared to analyst estimates of $581.84 million. During the same quarter in the previous year, the company posted $0.79 EPS. Enovis's revenue for the quarter was up 3.2% on a year-over-year basis. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. On average, equities analysts expect that Enovis will post 3.12 EPS for the current year.

Insider Buying and Selling at Enovis

In other Enovis news, insider Oliver Engert bought 1,200 shares of Enovis stock in a transaction dated Thursday, June 11th. The shares were purchased at an average cost of $21.62 per share, with a total value of $25,944.00. Following the completion of the purchase, the insider owned 51,840 shares of the company's stock, valued at approximately $1,120,780.80. This represents a 2.37% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In the last 90 days, insiders purchased 4,200 shares of company stock valued at $92,084. 2.90% of the stock is currently owned by company insiders.

Institutional Trading of Enovis

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ENOV. Dimensional Fund Advisors LP increased its position in Enovis by 1.8% during the 3rd quarter. Dimensional Fund Advisors LP now owns 2,971,545 shares of the company's stock valued at $90,156,000 after purchasing an additional 51,201 shares during the period. Rubric Capital Management LP purchased a new stake in shares of Enovis in the 3rd quarter worth about $83,435,000. Paradigm Capital Management Inc. NY lifted its position in shares of Enovis by 70.2% in the 1st quarter. Paradigm Capital Management Inc. NY now owns 1,776,715 shares of the company's stock worth $40,420,000 after purchasing an additional 732,917 shares during the period. River Road Asset Management LLC boosted its stake in shares of Enovis by 3.2% during the 4th quarter. River Road Asset Management LLC now owns 1,487,277 shares of the company's stock valued at $39,621,000 after purchasing an additional 46,289 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC boosted its stake in shares of Enovis by 38.0% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 1,045,360 shares of the company's stock valued at $24,430,000 after purchasing an additional 287,687 shares in the last quarter. Hedge funds and other institutional investors own 98.45% of the company's stock.

Enovis News Summary

Here are the key news stories impacting Enovis this week:

• Positive Sentiment: Enovis reported second-quarter adjusted earnings of $0.90 per share, above the $0.85 analyst consensus and up from $0.79 a year earlier. Revenue of $582.8 million was also slightly ahead of estimates, while sales increased 3.2% year over year. Enovis Q2 Earnings and Revenue Estimates
• Positive Sentiment: Management reaffirmed its full-year 2026 outlook, including revenue of approximately $2.3 billion to $2.4 billion and adjusted EPS guidance of $3.52 to $3.73. Reconstructive sales were a relative bright spot, rising 8% on a reported basis and 6% organically. Enovis Announces Second Quarter 2026 Results
• Positive Sentiment: BTIG Research raised its price target from $39 to $40 and maintained a Buy rating, implying substantial potential upside from recent trading levels. BTIG Research Price Target
• Neutral Sentiment: Wells Fargo lowered its price target modestly from $40 to $39 but retained an Overweight rating, indicating continued long-term confidence despite near-term concerns. Wells Fargo Price Target
• Negative Sentiment: The market reaction was negative because Enovis’ second-quarter performance was characterized as “softer than expected.” Although revenue and EPS exceeded published estimates, investors appear focused on the relatively modest 3% reported sales growth and the lack of an upward guidance revision. Enovis Shares Drop After Second-Quarter Earnings
• Negative Sentiment: Enovis continues to report a deeply negative GAAP net margin, which may reinforce investor concerns about profitability and execution even though adjusted earnings improved. Enovis Q2 2026 Earnings Call Transcript

Enovis Company Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source